Related Experiment Videos
Airway mucus hypersecretion in asthma: an undervalued pathology?
1Thoracic Medicine, National Heart & Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK. duncan.rogers@imperial.ac.uk
Current Opinion in Pharmacology
|May 14, 2004
Summary
Airway mucus hypersecretion in asthma indicates poor control and leads to airway obstruction. Research is identifying targets for new anti-hypersecretory drugs to treat this condition.
Area of Science:
- Pulmonary Medicine
- Respiratory Physiology
Background:
- Airway mucus hypersecretion is a key feature in asthma, signaling poor disease control.
- Excess mucus obstructs airways, increases airway hyperresponsiveness, and contributes to asthma morbidity and mortality.
Purpose of the Study:
- To investigate the specific mucus hypersecretory phenotype in asthma.
- To identify potential therapeutic targets for anti-hypersecretory drugs.
Main Methods:
- Review of existing literature on asthma pathophysiology and mucus production.
- Analysis of cellular and molecular mechanisms underlying mucus abnormalities in asthma.
Main Results:
- Asthma exhibits a distinct mucus hypersecretory phenotype, differing from other conditions like COPD.
- Key features include mucus plugging, MUC5B and MUC2 mucin alterations, and plasma exudation.
- Inflammatory mediators and neural pathways significantly impact mucus hypersecretion in asthma.
Conclusions:
- Understanding the specific mucus abnormalities in asthma is crucial for targeted treatment.
- Identifying novel targets for anti-hypersecretory drugs holds promise for improved asthma management.